EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Novel antimony-based antimicrobial drug targets membranes of Gram-positive and Gram-negative bacterial pathogens

Tarosha Salpadoru iD, Kevin E Pinks, Jacob A Lieberman, Kaitlyn Cotton, Karen L Wozniak, Nikolay Gerasimchuk, Marianna A Patrauchan iD

Microbiology Spectrum · 2024

DOI: 10.1128/spectrum.04234-23 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Microbiology Spectrum, 2024. Verfasst von Tarosha Salpadoru und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology and Molecular Genetics, Oklahoma State University, Stillwater, Oklahoma, USA. Hauptthemen laut MEDLINE: Microbial Sensitivity Tests, Antimony, Anti-Bacterial Agents, Gram-Negative Bacteria. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 91 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antimicrobial resistance (AMR) poses a significant worldwide public health crisis that continues to threaten our ability to successfully treat bacterial infections. With the decline in effectiveness of conventional antimicrobial therapies and the lack of new antibiotic pipelines, there is a renewed interest in exploring the potential of metal-based antimicrobial compounds. Antimony-based compounds with a long history of use in medicine have re-emerged as potential antimicrobial agents. We previously synthesized a series of novel organoantimony(V) compounds complexed with cyanoximates with a strong potential of antimicrobial activity against several AMR bacterial and fungal pathogens. Here, five selected compounds were studied for their antibacterial efficacy against three important bacterial pathogens: Pseudomonas aeruginosa , Escherichia coli , and Staphylococcus aureus . Among five tested compounds, SbPh 4 ACO showed antimicrobial activity against all three bacterial strains with the MIC of 50–100 µg/mL. The minimum bactericidal concentration/MIC values were less than or equal to 4 indicating that the effects of SbPh 4 ACO are bactericidal. Moreover, ultra-thin electron microscopy revealed that SbPh 4 ACO treatment caused membrane disruption in all three strains, which was further validated by increased membrane permeability. We also showed that SbPh 4 ACO acted synergistically with the antibiotics, polymyxin B and cefoxitin used to treat AMR strains of P. aeruginosa and S. aureus , respectively, and that at synergistic MIC concentration 12.5 µg/mL, its cytotoxicity against the cell lines, Hela, McCoy, and A549 dropped below the threshold. Overall, the results highlight the antimicrobial potential of novel antimony-based compound, SbPh 4 ACO, and its use as a potentiator of other antibiotics against both Gram-positive and Gram-negative bacterial pathogens. IMPORTANCE Antibiotic resistance presents a critical global public health crisis that threatens our ability to combat bacterial infections. In light of the declining efficacy of traditional antibiotics, the use of alternative solutions, such as metal-based antimicrobial compounds, has gained renewed interest. Based on the previously synthesized innovative organoantimony(V) compounds, we selected and further characterized the antibacterial efficacy of five of them against three important Gram-positive and Gram-negative bacterial pathogens. Among these compounds, SbPh 4 ACO showed broad-spectrum bactericidal activity, with membrane-disrupting effects against all three pathogens. Furthermore, we revealed the synergistic potential of SbPh 4 ACO when combined with antibiotics, such as cefoxitin, at concentrations that exert no cytotoxic effects tested on three mammalian cell lines. This study offers the first report on the mechanisms of action of novel antimony-based antimicrobial and presents the therapeutic potential of SbPh 4 ACO in combating both Gram-positive and Gram-negative bacterial pathogens while enhancing the efficacy of existing antibiotics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Microbial Sensitivity TestsAntimonyAnti-Bacterial AgentsGram-Negative BacteriaHumansGram-Positive BacteriaEscherichia coliPseudomonas aeruginosaStaphylococcus aureusCell Membrane

Stichwörter der Autor:innen

broad spectrumcombination therapycytotoxicity

Substanzen

AntimonyAnti-Bacterial Agents

Autor:innen und Institutionen

  • Department of Microbiology and Molecular Genetics, Oklahoma State University, Stillwater, Oklahoma, USA.
  • Department of Chemistry and Biochemistry, Missouri State University, Springfield, Missouri, USA.

ORCID-Profile: Tarosha Salpadoru, Marianna A Patrauchan

Zitieren

APA

Salpadoru, T., Pinks, K. E., Lieberman, J. A., Cotton, K., Wozniak, K. L., Gerasimchuk, N., & Patrauchan, M. A. (2024). Novel antimony-based antimicrobial drug targets membranes of Gram-positive and Gram-negative bacterial pathogens. Microbiology Spectrum. https://doi.org/10.1128/spectrum.04234-23

Vancouver

Salpadoru T, Pinks KE, Lieberman JA, Cotton K, Wozniak KL, Gerasimchuk N, et al. Novel antimony-based antimicrobial drug targets membranes of Gram-positive and Gram-negative bacterial pathogens. Microbiology Spectrum. 2024. doi:10.1128/spectrum.04234-23

BibTeX
@article{Salpadoru2024,
  author = {Salpadoru, Tarosha and Pinks, Kevin E and Lieberman, Jacob A and Cotton, Kaitlyn and Wozniak, Karen L and Gerasimchuk, Nikolay and Patrauchan, Marianna A},
  title = {Novel antimony-based antimicrobial drug targets membranes of Gram-positive and Gram-negative bacterial pathogens},
  journal = {Microbiology Spectrum},
  year = {2024},
  doi = {10.1128/spectrum.04234-23}
}
Kostenlos starten →